This new vaccine, authorized this weekend in the United States, has many advantages over others. Explanations.
After its authorization this weekend in the United States, the Johnson & Johnson vaccine should in turn be approved in Europe in early March. The Minister for Industry Agnès Pannier-Runacher declared this Sunday February 28 on France 3 that it could be distributed at the end of the month or at the beginning of April. It would thus be the fourth vaccine to join the arsenal already used with Pfizer / BioNTech, Moderna and Astra Zeneca in France.
Unlike the Pfizer / BioNTech and Moderna vaccines which work from Messenger RNA, Johnson & Johnson is a “viral vector” vaccine. The researchers use an adenovirus to which is added a fragment of covid-19. Once vaccinated, the person triggers an immune response.
A single dose
The Johnson & Johnson vaccine is administered as a single dose. The prescription could change after the publication of the results of the study currently conducted with two doses. The vaccine was found to be 66% effective in preventing moderate to severe forms of COVID-19 four weeks after inoculation, and 100% effective in preventing hospitalizations and death from the virus. This rate is lower than the Messenger RNA vaccines from Pfizer (95%) or Moderna (92%). According to Johnson & Johnson, the vaccine does not cause any adverse effects as it is important. Some patients have reported mild headaches, pain in the arm, and fatigue.
A lower price
The group should sell its vaccine at cost price of € 6.93. Moderna’s vaccine costs € 15 per dose, Pfizer / BioNTech’s vaccine costs € 15.50 and AstraZeneca costs € 2.
Storage in the fridge
Another advantage of the Johnson & Johnson vaccine: it can be stored in the fridge between 2 ° and 8 °. This simplifies the logistical issues compared to the Pfizer / BioNTech vaccine which must be stored at – 80 °. No more storage problems with doctors or pharmacists or transport problems.
Made in France
The vaccine will be partly manufactured in France. Sanofi has committed to producing the Pfizer-BioNTech vaccine at its Marcy-l’Etoile site near Lyon, from the third quarter, at a rate of 12 million doses per month. The laboratory will also produce 125 million doses of the messenger RNA vaccine developed by Pfizer-BioNTech this summer at its factory in Frankfurt.